Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. Case Rep Oncol 2020;13(1):456-461
Date
05/14/2020Pubmed ID
32399016Pubmed Central ID
PMC7204854DOI
10.1159/000506625Scopus ID
2-s2.0-85084410749 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient's tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.